Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10964199 | Vaccine | 2015 | 8 Pages |
Abstract
This study led to better multi-sectoral collaboration and improved national capacity to perform economic evaluations. Routine infant vaccination against Streptococcus pneumoniae would be highly cost-effective in Georgia. The decision to introduce PCV10 was already made some time before the study was initiated but it provided important economic evidence in support of that decision. There are several uncertainties around many of the parameters used, but a multivariate scenario analysis with several conservative assumptions (including no herd effect in older individuals) shows that this recommendation is robust. This study supports the decision to introduce PCV10 in Georgia.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
T. Komakhidze, C. Hoestlandt, T. Dolakidze, M. Shakhnazarova, R. Chlikadze, N. Kopaleishvili, K. Goginashvili, M. Kherkheulidze, A.D. Clark, J. Blau,